Colin Foster,

Colin has thirty years of experience as a public and private life science company Chairman, Executive Chairman, Board Member, CEO, and entrepreneur with direct leadership experience across the D-manufacturing-commercial continuum in therapeutics, diagnostics, medical devices, and over-the-counter (OTC) consumer healthcare products.  As CEO, he has led multi-billion-dollar, mid-
sized, and start-up life science companies/divisions in the USA, Canada, Israel, and the United Kingdom/Ireland, financing, building, turning around, and optimizing them organically and through
transformational transactions.

He is currently Co-founder, Chairman, and CEO of Cytosolix, Inc., a venture-backed oncology company spun out of Yale University, Co-founder; Chairman of Saatient Therapeutics, Inc., an oncology company spun out of Columbia University, a Board Member of NBO Pharma, Inc., a clinical stage CNS; rare disease company, an Entrepreneur-in-Residence at Yale University, an Executive-in-Residence at Columbia University, and a member of the New York University (NYU) Langone Health Investment Advisory Committee.

Previously, Colin was CEO of iSci Management, a strategic advisory firm, Board Member of Ascendia Pharmaceuticals, a private equity-backed CDMO, Board Member, CEO of Bioblast Pharma Ltd, a publicly traded (NASDAQ), clinical-stage biopharma company, Executive Chairman of Ivenix, Inc., a US-based venture-backed medical device company, and a Co-founder, Board Member, and CEO of Optherion, Inc., a venture-backed ophthalmology rare disease therapeutics and molecular diagnostics company.

Colin was the President and CEO of Bayer Pharmaceuticals Corporation, USA, and the Region Head of the North American Pharmaceuticals Group of Bayer AG, and a member of Bayer AG’s Global Pharmaceutical Operating Committee.  Over ten years with Bayer in therapeutics, medical devices, and diagnostics, he held progressive commercial and general management roles in Canada, the USA, and the United Kingdom/Ireland, culminating in his role as CEO of the multi-billion-dollar North American Pharmaceuticals Group.

Colin has a B.Sc. in Zoology and Microbiology from the University of Toronto, an M.B.A. from the Ivy School of Business at Western University in Canada, and his Canadian Securities Certificate. He is a citizen of Canada, the United States of America, and the United Kingdom.